Science News for ACC.21
The American Heart Association's Science News from ACC.21 coverage brings you results and insights into selected important scientific trials presented at ACC.21, a virtual conference held May 15-17, 2021. Find at-a-glance data summaries, exclusive interviews, simultaneous publications, and more – all in one place.
Jump to one day's coverage: Saturday | Sunday | Monday
Quick Reference:
AHA Journals Simultaneous Publications
Saturday's Selected Science
PARADISE-MI
Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction
Marc A. Pfeffer, MD, PhD | Distinguished Dzau Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
- RESULTS: PARADISE-MI: Heart Failure drug sacubitril/valsartan does not outperform ACE inhibitor after heart attack
- ClinicalTrials: NCT02924727
- PARADISE-MI Presentation Slides (PDF)
- PARADISE-MI Data Summary Slide (PDF)
PARADISE-MI Results
Investigator Marc Pfeffer, MD, PHD summarizes the results of PARADISE-MI.
ADAPTABLE
Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
Schuyler Jones, MD | Duke University Medical Center, Durham, NC
- RESULTS: ADAPTABLE: Low-dose aspirin is as effective and safe as a higher dose in secondary prevention of cardiovascular events
- ClinicalTrials: NCT02697916
- ADAPTABLE Trial Home
- ADAPTABLE Presentation Slides (PDF)
- ADAPTABLE Data Summary Slide (PDF)
ADAPTABLE Study Results
Erin Michos, MD, MHS, FAHA interviews Schuyler Jones, MD about the results of ADAPTABLE.
Sunday's Selected Science
DARE-19
Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 - Main Results From The DARE-19 Randomized Trial
Mikhail Kosiborod, MD | Saint Luke's Mid America Heart Institute, Kansas City, MO
- RESULTS: DARE-19 failed to capture enough events to achieve statistical significance on its primary endpoints, but suggests dapagliflozin is safe for COVID-19 patients
- Clinical Trials: NCT04350593
- DARE-19 Presentation Slides (PDF)
- DARE-19 Data Summary Slide (PDF)
DARE-19 Results
Sandeep Das, MD interviews investigator Mikhail Kosiborod, MD about the results of DARE-19.
Monday's Selected Science
CONNECT-HF
Care Optimization Through Patient And Hospital Engagement Clinical Trial For Heart Failure: Primary Results Of The Connect-hf Randomized Clinical Trial
Adam D. DeVore, MD, MHS | Duke Clinical Research Institute, Durham, NC
- RESULTS: Extending existing hospital-based quality improvement efforts through audit, feedback, and education did not improve clinical outcomes or quality of care for patients with heart failure with reduced left ventricular ejection fraction.
- Clinical Trials: NCT03035474
- CONNECT-HF Presentation Slides (PDF)
- CONNECT-HF Data Summary Slide (PDF)
CONNECT-HF Results
Larry Allen, MD, MHS interviews investigator Adam DeVore, MD, MHS about the results of CONNECT-HF.
HOLIDAY Monitors Study
Acute Alcohol Consumption And Discrete Atrial Fibrillation Events
Gregory M Marcus, MD, MAS | University of California, San Francisco, San Francisco, CA
- RESULTS: HOLIDAY Monitors Study: Acute alcohol consumption found to be associated with discrete atrial fibrillation events.
- Clinical Trials: NCT01996943
- HOLIDAY Monitors Study Presentation Slide (PDF)
- HOLIDAY Monitors Study Data Summary Slide (PDF)
HOLIDAY Monitors Study Results
Sana M. Al-Khatib, MD, MHS interviews Gregory Marcus, MD, MAS about the results of the HOLIDAY Monitors Study.
Other Late Breaking Science & Simultaneous Publications from ACC.21
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
Siri Lagethon Heck, et al. | Circulation | May 16, 2021
Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS
Kristina Lambrakis, et al. | Circulation | May 16, 2021
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure with Preserved Ejection Fraction
Senthil Selvaraj, et al. | JAHA | May 16, 2021
Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Arash A Nargesi, et al. | JAHA | May 15, 2021
Temporal Trends, Clinical Characteristics and Outcomes of Emergent Coronary Artery Bypass Grafting for Acute Myocardial Infarction in the United States
Sri Harsha Patlolla, et al. | JAHA | May 15, 2021
Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry
Sameed Ahmed M, et al. | Circulation: Heart Failure | May 15, 2021
Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction
Sean P. Murphy, et al. | Circulation: Heart Failure | May 15, 2021
Social Determinants of Adherence to COVID-19 Risk Mitigation Measures Among Adults with Cardiovascular Disease
Kobina K., et al. | Circulation: Cardiovascular Quality and Outcomes | May 6, 2021
Hospital Variation in 30‐Day Readmissions Following Transcatheter Aortic Valve Replacement
Dhaval Kolte., et al. | JAHA | May 3, 2021